Загрузка...
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as the driver mutation of the majority of non- BCR-ABL1 myeloproliferative neoplasms (MPNs). Subsequently, the search for JAK2 inhibitors continued with the discovery that the other driver mutations ( CALR and MPL) a...
Сохранить в:
| Опубликовано в: : | F1000Res |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
F1000 Research Limited
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773931/ https://ncbi.nlm.nih.gov/pubmed/29399328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.13167.1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|